Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab covalently linked to the topoisomerase I inhibitor deruxtecan. From Wikipedia
The pharmaceutical giant cites reduced government support and an unfavorable business environment as key factors in its decision.
